Company intelligence / Profile preview
Luye Pharma Group
Yantai, Chinaluye.cn ↗
- Ownership
- Public · 2186
- Employees
- ~10000
- Development stage
- Commercial
01
Overview
Luye Pharma has received approval for 16 innovative products in multiple global markets since 2021. Notable recent approvals include Rykindo® and Erzofri® by the FDA, with Rykindo® being the first innovative CNS drug developed by a Chinese company approved for the U.S. market.
- Therapeutic areas
- OncologyPsychiatryNeurology
- Modalities
- Small moleculesmicrospheresliposomestransdermal systemsantibodiesnucleic acidsmRNAcell therapy (CAR-T)
- Industry
- Biotech
02
Drug pipeline
31 assets30 more assets in the full pipeline.
Request access →03
Partnerships
AstraZenecaAcino
Beyond the preview
Go deeper on Luye Pharma Group.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Luye Pharma Group.